taxinine and Carcinoma--Squamous-Cell

taxinine has been researched along with Carcinoma--Squamous-Cell* in 1 studies

Other Studies

1 other study(ies) available for taxinine and Carcinoma--Squamous-Cell

Article	Year
Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer. Bioorganic & medicinal chemistry letters, 2004, Sep-20, Volume: 14, Issue:18 Three novel taxinine analogues were prepared and tested for their activity as multidrug resistance (MDR) reversal agents in comparison with verapamil. In vitro testing demonstrated that compounds 8-10 possess MDR-reversal activity in the KB/V cell line. Half-hour after treatment with 5, 10, and 20 micromol/L compound 9, the intracellular rhodamine123 concentration increased 2.3, 2.9, and 3.2-fold, respectively, higher than 1.88-fold of 10 micromol/L verapamil in KB/V cell line. In vivo studies with VCR-resistant KB/V tumor xenografts showed that compound 9 in combination with VCR significantly inhibited tumor growth. Treatment with VCR or 9 alone did not result in growth inhibition. These results reveal that three taxinine analogues are good modifiers of MDR in tumor cells. Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Taxoids; Time Factors; Vincristine; Xenograft Model Antitumor Assays	2004

Article

Year

Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer.

Bioorganic & medicinal chemistry letters, 2004, Sep-20, Volume: 14, Issue:18

Three novel taxinine analogues were prepared and tested for their activity as multidrug resistance (MDR) reversal agents in comparison with verapamil. In vitro testing demonstrated that compounds 8-10 possess MDR-reversal activity in the KB/V cell line. Half-hour after treatment with 5, 10, and 20 micromol/L compound 9, the intracellular rhodamine123 concentration increased 2.3, 2.9, and 3.2-fold, respectively, higher than 1.88-fold of 10 micromol/L verapamil in KB/V cell line. In vivo studies with VCR-resistant KB/V tumor xenografts showed that compound 9 in combination with VCR significantly inhibited tumor growth. Treatment with VCR or 9 alone did not result in growth inhibition. These results reveal that three taxinine analogues are good modifiers of MDR in tumor cells.

Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Taxoids; Time Factors; Vincristine; Xenograft Model Antitumor Assays

2004